Edition:
India

People: CytomX Therapeutics Inc (CTMX.OQ)

CTMX.OQ on NASDAQ Stock Exchange Global Select Market

7.40USD
18 Sep 2020
Change (% chg)

$0.22 (+3.06%)
Prev Close
$7.18
Open
$7.27
Day's High
$7.44
Day's Low
$7.05
Volume
464,865
Avg. Vol
222,699
52-wk High
$15.43
52-wk Low
$3.60

Galli, Nick 

Mr. Nick Galli, J.D. is Senior Vice President, Chief Business Officer of the company. Mr. Galli brings more than 15 years of transactions experience, most of which has been focused in the biotechnology industry. Most recently, Mr. Galli held the position of vice president, business development at Denali Therapeutics where he led the execution of more than twenty collaborations, including strategic partnerships with Sanofi-Genzyme, Takeda, Genentech and F-star. Prior to Denali, Mr. Galli was senior director, transactions at Johnson & Johnson Innovation Center. Prior to this, Mr. Galli held roles of increasing responsibility at Genentech within the business development and transactional law groups. Mr. Galli began his career as a corporate attorney at the law offices of Skadden, Arps, Slate, Meagher & Flom and practiced in the technology transactions group at Wilson Sonsini Goodrich & Rosati. Mr. Galli received his B.A. degree from Princeton University and his J.D. from the Georgetown University Law Center.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Sean McCarthy

3,769,930

Carlos Campoy

--

Amy Peterson

3,395,720

W. Michael Kavanaugh

1,477,000

Lloyd Rowland

1,097,840

Nick Galli

--
As Of  31 Dec 2019